Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1369568

Catalyst Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCatalyst Pharmaceuticals, Inc. (CPRX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, reporting, regulation-fd

TL;DR

Catalyst Pharma filed a standard 8-K, no major news.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This filing indicates routine corporate reporting and does not appear to contain new material information that would immediately impact the company's stock price.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no disclosed material events or financial changes.

Key Players & Entities

  • CATALYST PHARMACEUTICALS, INC. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • 355 Alhambra Circle Suite 801 Coral Gables , Florida 33134 (address) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The earliest event reported in this filing is January 13, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134.

What is the company's Central Index Key (CIK)?

The company's Central Index Key (CIK) is 0001369568.

What is the company's Standard Industrial Classification (SIC) code?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-13 06:07:03

Key Financial Figures

  • $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Form 8-K, and the corporate presentation contain forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in the Company's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website, or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein or therein, which speak only as of this date. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: January 13, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.